A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco

Sponsor

Pfizer (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05997485

Collaborator

(none)

150

Enrollment

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of this study is to collect information on the:

general information of a group of people such as their age, sex, and other facts.
clinical information of the patients such as any other illness before having COVID 19.

In adult patients with COVID-19 who have been prescribed nirmatrelvir and ritonavir treatment.

This study will be conducted in Morocco. The study will capture information of the adult COVID-19 outpatients and inpatients who have been prescribed nirmatrelvir, ritonavir treatment. The inpatients will be admitted in the hospital for other reasons than COVID-19.

This study will have about 150 patients. The study will involve collection of patient information from medical records. The information collected can be either from papers or from computers.

The study will include patient information of those who:

are confirmed to have COVID-19 infection during the study period from 01 June 2022 to 30 June 2023.
are 18 years of age or older.
are prescribed Nirmatrelvir and ritonavir. This study will help to inform decision-making on use of Paxlovid at the national level.

Condition or Disease	Intervention/Treatment	Phase
COVID-19 Drug Treatment	Drug: Nirmatrelvir/Ritonavir

Study Design

Study Type:

Observational

Anticipated Enrollment :

150 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

A Retrospective Observational Non-Interventional Study (NIS) to Assess Patient Characteristics Among COVID-19 Patients Receiving Treatment With Nirmatrelvir/Ritonavir (PAXLOVIDTM) in Morocco.

Anticipated Study Start Date :

Oct 1, 2023

Anticipated Primary Completion Date :

Apr 30, 2024

Anticipated Study Completion Date :

May 31, 2024

Arms and Interventions

Arm	Intervention/Treatment
Participants receiving Paxlovid Treatment Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid.	Drug: Nirmatrelvir/Ritonavir Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid. Other Names: Paxlovid

Arm

Intervention/Treatment

Participants receiving Paxlovid Treatment

Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid.

Drug: Nirmatrelvir/Ritonavir

Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid.

Other Names:

Paxlovid

Outcome Measures

Primary Outcome Measures

Demographical Characteristics of Participants [Approximately 01 June 2022 through 30 June 2023]
Clinical Characteristics of Participants [Approximately 01 June 2022 through 30 June 2023]
Number of Participants with Pre-existing Comorbidites [Approximately 01 June 2022 through 30 June 2023]